Intra-Cellular Therapies, Inc.
NASDAQ Global SelectTotal Valuation
Intra-Cellular Therapies, Inc. carries a market capitalization of 14.05B, placing it among publicly traded companies globally. Its enterprise value stands at 7.55B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 14.05B |
| Enterprise Value | 7.55B |
Share Statistics
Intra-Cellular Therapies, Inc. currently has 106.24M shares outstanding.
| Shares Outstanding | 106.24M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 12.53, and the price-to-book ratio stands at -5.04.
| PE Ratio | N/A |
| PS Ratio | 12.53 |
| PB Ratio | -5.04 |
| P/TBV Ratio | 7.43 |
| P/FCF Ratio | -116.99 |
| P/OCF Ratio | -116.56 |
Enterprise Valuation
| EV / Sales | 11.09 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Intra-Cellular Therapies, Inc. maintains a current ratio of 6.36, meaning it holds 6.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.36 |
| Quick Ratio | 5.68 |
| Debt / Equity | 1.48 |
| Debt / EBITDA | -0.15 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -7.13 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.00 |
Taxes
| Income Tax | 473,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Intra-Cellular Therapies, Inc.'s stock has gained approximately 87.47512% over the past 52 weeks. The 50-day moving average sits at 129.42, while the 200-day moving average is 92.67.
| Beta (5Y) | N/A |
| 52-Week Price Change | 87.47512% |
| 50-Day Moving Average | 129.42 |
| 200-Day Moving Average | 92.67 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Intra-Cellular Therapies, Inc. generated 680.50M in revenue and converted that into -74.68M in net income, yielding earnings per share of -0.73. EBITDA reached -116.21M, while operating income came in at -116.72M.
| Revenue | 680.50M |
| Gross Profit | 623.54M |
| Operating Income | -116.72M |
| Pretax Income | -74.20M |
| Net Income | -74.68M |
| EBITDA | -116.21M |
| EBIT | -116.72M |
| Earnings Per Share (EPS) | -0.73 |
Balance Sheet
Intra-Cellular Therapies, Inc. holds 1.00B in cash and equivalents against 16.98M in total debt, resulting in a net debt position of -306.95M. Total book value stands at -1.69B, with working capital of 1.10B providing operational flexibility.
| Cash & Cash Equivalents | 1.00B |
| Total Debt | 16.98M |
| Net Debt | -306.95M |
| Equity (Book Value) | -1.69B |
| Book Value Per Share | -16.57 |
| Working Capital | 1.10B |
Cash Flow
Intra-Cellular Therapies, Inc. produced -73.18M in operating cash flow over the past twelve months. After subtracting -269,000.00 in capital expenditures, free cash flow totaled -73.45M - equivalent to -0.72 per share.
| Operating Cash Flow | -73.18M |
| Capital Expenditures | -269,000.00 |
| Free Cash Flow | -73.45M |
| FCF Per Share | -0.72 |
Margins
Intra-Cellular Therapies, Inc. operates with a gross margin of 91.63, reflecting its pricing power and cost economics. The operating margin of -17.15 and net profit margin of -10.97 provide insight into operational efficiency.
| Gross Margin | 91.63 |
| Operating Margin | -17.15 |
| Pretax Margin | -10.90 |
| Profit Margin | -10.97 |
| EBITDA Margin | -17.08 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -6.65 |
| FCF Yield | -0.85 |
Scores
Intra-Cellular Therapies, Inc. posts an Altman Z-Score of 22.88, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 22.88 |